Cancer Clinical Trial
Official title:
Relations Between Cognitive Complaints and Cognitive Scores Goals in Cancer: Assessment of Metamemory
This pilot study is, in this new and original approach in cancer pathology, measure and explain the correspondence between perceived cognitive impairment (cognitive complaint) by cancer patients and their cognitive scores goals with tasks metamemory while controlling the anxiety and depression and fatigue factors of patients.
The relationship between performance from neuropsychological tests and subjective complaints
of cancer patients treated with chemotherapy or adjuvant hormone therapy is not clear, many
studies have reported no significant correlation between these two measures: the perception
of patients' their cognitive deficits is generally increased relative to that which is
measured by neuropsychological testing.
The reason for this lack of association found is probably multifactorial. 1) It can be
explained in part by methodological limitations in some studies (lack of sensitivity tests,
experimental design). 2) psycho-order factors and fatigue are also an explanatory variable
in the sense that literature data often show that cognitive complaints are correlated with
levels of anxiety and depression and fatigue. 3) Finally, metacognition, often assessed in
neurodegenerative diseases or even in normal aging to better understand its impact on
cognitive disorders, including memory impairment, and the complaint has never been explored
in patients with cancer.
Metacognition is a complex but highly sensitive to measure and understand the patient's
complaint and correspondence or disagree with the actual performance concept. Metacognition
refers A) metacognitive knowledge, ie knowledge of an individual's own cognitive processes;
This is a non-dependent activity during which, upstream of the performance of any task,
implement an appropriate strategy, anticipate and plan cognitive steps that would be
necessary for its success general knowledge; and B) metacognitive experiences, ie knowledge
that is based on a cognitive activity in progress, which allows to monitor and control the
task in order to maintain or otherwise modify the cognitive processes involved.
While metacognitive knowledge (A) are assessed by multiple choice questionnaires,
metacognitive experiences (B) allow targeted and precise fine measures of correspondence
between the prediction performance by the patient himself and his actual performance a
mnemonic task (for JOL and FOK Judgment of Learning for Feeling Of Knowing). Studies
exploring the effects of age on metamemory usually show a deficit of these metacognitive
experiences in normal aging compared to young subjects.
Collected at the time of learning, JOL is a prediction of future performance for information
that have just been learned. More specifically, when learning words, the subject must judge
its ability to further free recall for each item (quantitative data). This prediction is
then compared to the actual memory performance found in the free recall task. This
comparison allows to judge the accuracy of the prediction and therefore the accuracy of
metamemory judgment.
The FOK corresponds to a prediction of performance information that could not be provided in
free recall recognition. In practice, when an item is not recovered in free recall, the
subject must judge its ability to recognize the correct answer among distractor responses.
Metacognitive processes can refer to the field of memory (metamemory) or attention
(métaattention), but for now metamemory was much valued neuropsychological tests and the
testing and are most successful and many more.
;
Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
| Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
| Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
| Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
| Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
| Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
| Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
| Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
| Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
| Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
| Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
| Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
| Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|